These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3942399)

  • 1. [Immunotherapy, with OK-432 for cases of nasopharyngeal carcinoma].
    Tsukuda M; Tamamushi N; Mochimatsu I; Mitarai K; Kaneko M; Sawaki S
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):53-9. PubMed ID: 3942399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical value of long-term administration of OK-432 in head and neck cancer].
    Mitarai K; Tsukuda M; Tamamushi N; Mochimastu I; Kubota A; Sawaki S
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):945-50. PubMed ID: 3963858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of Su-polysaccharide (Su-PS) skin test in patients with primary lung cancer treated with chemotherapy and administration of OK-432, with special reference to the therapeutic effect and prognosis].
    Horiuchi M; Sato K; Nakarai I; Shinoda A
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):468-74. PubMed ID: 2181937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunotherapy of terminal-stage malignant tumors with the immunopotentiator OK-432--a comparison between SU-PS test-responder and -nonresponder patients].
    Yagi Y; Yagi S; Ichiki H
    Gan No Rinsho; 1987 Jun; 33(7):815-21. PubMed ID: 3302349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of immune skin reactions in progressive lung cancer during the administration of OK-432--relation to reactions to DNCB, PPD and Su-PS].
    Katada H; Nishikawa K; Yoneda T; Kitamura H; Nakajima A; Mikami R
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):61-70. PubMed ID: 3026256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relation between prognosis and the Su-PS skin reaction in patients with non-resected primary lung cancer receiving OK-432].
    Nakarai I; Rikitake H; Koga T; Hayashi A; Harada Y; Takamoto M; Ishibashi T; Shinoda A; Sagawa K
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3050-7. PubMed ID: 2823723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of OK-432 in the treatment of primary lung cancer].
    Kishimoto T; Okada K
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The Su-polysaccharide skin test in lung cancer].
    Harada J; Horiguchi T; Oki K; Miyamoto H; Osada T
    Gan To Kagaku Ryoho; 1987 Sep; 14(9):2697-702. PubMed ID: 3307634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer.
    Watanabe Y; Iwa T
    J Biol Response Mod; 1987 Apr; 6(2):169-80. PubMed ID: 3585412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Su-polysaccharide skin test and immunotherapy with OK-432 in postoperative gastric cancer--the effect of a splenectomy].
    Saito H; Kikkawa H; Bando H; Sakatoku M; Hirano M; Tatsuzawa T
    Gan No Rinsho; 1988 Nov; 34(14):1965-8. PubMed ID: 3204664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer].
    Kikkawa N; Sasai H; Kawahara T
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2163-9. PubMed ID: 6486832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy for lung cancer by streptococcal preparation OK-432].
    Watanabe Y; Shimizu J; Yoshida Y; Hashizume Y; Yamada T; Iwa T
    Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1432-5. PubMed ID: 2586434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of immunotherapy using the non-specific immunopotentiator OK-432 in malignant ovarian tumors--selecting appropriate cases for immunotherapy].
    Nishida Y; Sakakibara K; Kano T; Ohta M; Tomoda Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul; 38(7):1017-25. PubMed ID: 3746020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological basis and immunotherapy of nasopharyngeal carcinoma.
    Tsukuda M; Sawaki S
    Auris Nasus Larynx; 1985; 12 Suppl 2():S161-5. PubMed ID: 3939185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of a skin test (SU-PS) for immune responses in patients with gastrointestinal cancer treated with OK-432].
    Miyamoto Y; Takeshita M; Izuo M
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3229-35. PubMed ID: 3777960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Randomized controlled study of OK-432 in the treatment of cancerous pleurisy].
    Urata A; Nishimura M; Ota K
    Gan To Kagaku Ryoho; 1983 Jun; 10(6):1497-503. PubMed ID: 6409006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological differences between squamous cell cancer patients treated with and without biological response modifier (OK-432): evaluation at a period of more than one year after the last treatment.
    Yoshimura Y; Oka M; Harada T; Inou Y; Saito H; Odagawa T; Matsumoto K
    J Osaka Univ Dent Sch; 1989 Dec; 29():117-22. PubMed ID: 2577382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of NK activity in regional lymph nodes by preoperative immunotherapy with OK-432 in patients with cancer of the oral cavity.
    Vinzenz K; Matejka M; Watzek G; Porteder H; Neuhold N; Micksche M
    Cancer Detect Prev Suppl; 1987; 1():463-75. PubMed ID: 3480060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)].
    Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
    Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):799-811. PubMed ID: 2196311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of patients with terminal-stage malignant tumors with an immunopotentiator OK-432--a comparison of SU-PS test-responding and -nonresponding patients.
    Yagi Y; Yagi S
    Int J Immunopharmacol; 1988; 10(4):451-61. PubMed ID: 3049405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.